Does azathioprine raise liver enzymes?

Does Azathioprine Raise Liver Enzymes?

Yes, azathioprine can raise liver enzymes and cause hepatotoxicity, which is why regular monitoring of liver function tests is mandatory throughout treatment. 1

Incidence and Clinical Significance

Hepatotoxicity from azathioprine is uncommon but well-recognized, occurring in less than 1% of rheumatoid arthritis patients but more frequently in transplant recipients 2. The FDA label confirms that hepatotoxicity manifests as elevation of serum alkaline phosphatase, bilirubin, and/or serum transaminases 2.

Patterns and Timing of Liver Enzyme Elevation

The liver injury from azathioprine presents in several patterns:

• Mixed pattern (50%) - most common
• Cholestatic pattern (37.5%)
• Hepatocellular pattern (12.5%) 3

Critical Timing Considerations

Most hepatotoxicity occurs within the first few months of treatment, particularly during the first 6 months in transplant recipients 2. However, a crucial caveat: liver injury can occur even after years of stable therapy 4, 5. One case documented severe cholestatic injury after 22 months of treatment 5, and another after multiple years without issue 4.

Nearly three-quarters of patients present with self-limited cholestatic hepatitis, typically within 3 months of starting therapy or after a dose increase 6. Importantly, 59% of cases arise after dose escalation, with median latency of 44 days post-increase 6.

Mandatory Monitoring Protocol

The British Association of Dermatologists guidelines provide the definitive monitoring schedule 1, 7:

Initial Phase

• Weekly liver function tests (LFTs) for the first 4 weeks or until maintenance dose is achieved
• More frequent than weekly monitoring for higher doses or patients with hepatic/renal impairment

Maintenance Phase

• Minimum of once every 3 months for the duration of therapy
• Return to weekly monitoring after any dose increase

High-Risk Situations Requiring Enhanced Monitoring

• Patients with pre-existing hepatic dysfunction 1
• Concurrent corticosteroid therapy (may increase hepatotoxicity risk) 8
• Hepatitis B or C carriers (screen before initiating) 1

Clinical Presentation

Symptomatic hepatotoxicity presents with:

• Jaundice
• Abdominal pain
• Fatigue
• Elevated aminotransferases in cholestatic pattern 4

Asymptomatic elevation is more common, detected only through routine monitoring 3.

Management Algorithm

When Liver Enzymes Elevate:

1. Immediate assessment: Rule out other causes (viral hepatitis, particularly EBV in immunosuppressed patients) 1

2. Mild elevation (ALT/AST 2-3x ULN): Consider dose reduction 1, 7

3. Significant elevation or cholestasis: Discontinue azathioprine immediately 7

4. If using azathioprine-allopurinol co-therapy: Increasing allopurinol from 100 to 200-300 mg/day significantly lowered liver enzymes in 5/6 patients with hepatotoxicity 9

Expected Recovery

• Most patients recover fully after drug withdrawal
• Median recovery time: 41 days 3
• Severe cholestasis can occur but typically resolves 3
• One study showed resolution within 3 weeks of discontinuation 8

Critical Pitfalls to Avoid

1. Don't assume safety based on treatment duration: Hepatotoxicity can occur after years of stable therapy 4, 5

2. Don't overlook dose escalations: Nearly 60% of cases occur after dose increases 6

3. Don't continue therapy with persistent LFT abnormalities: If abnormalities persist despite withdrawal, investigate alternative causes 1

4. Don't use in patients with pre-existing cirrhosis without extreme caution: One patient with cirrhosis required liver transplantation 6

Special Populations

Patients with hepatic dysfunction: The Summary of Product Characteristics advises cautious administration with regular monitoring, as drug metabolism may be impaired 1. Dosage should be at the lower end of the normal range and reduced if hepatotoxicity occurs.

Pregnant women: Postmarketing cases of intrahepatic cholestasis of pregnancy have been reported; discontinue if this develops 2.

The prognosis for azathioprine-induced hepatotoxicity is generally favorable with prompt recognition and drug withdrawal, except in patients with preexisting cirrhosis 6.